Trial Profile
A phase I/II trial of TAS-102 in combination with irinotecan in Japanese patients with advanced gastric cancer refractory to standard chemotherapies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Mar 2022
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms T-SCAN study
- 12 Mar 2022 Results published in the Investigational New Drugs
- 17 Jan 2021 Results assessing recommended dose of trifluridine/tipiracil and irinotecan presented at the 2021 Gastrointestinal Cancers Symposium
- 19 Aug 2020 Planned End Date changed from 31 May 2019 to 31 May 2020.